Surprising, both the non-squamous EGFR-mutant NSCLC group and the squamous NSCLC had a less robust response regardless of c-Met expression with ORR ranging from 11.1% to 16.7%, which prompted the closure of these cohorts/cessation of enrollment per study protocol [73]. The gene discussed is MET; the disease is non-small cell lung carcinoma.